# PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)

> **NCT03983876** · PHASE1 · COMPLETED · sponsor: **Alvotech Swiss AG** · enrollment: 207 (actual)

## Conditions studied

- Phase 1

## Interventions

- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT03983876
- **Lead sponsor:** Alvotech Swiss AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-01
- **Primary completion:** 2019-12-03
- **Final completion:** 2019-12-03
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2022-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03983876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03983876, "PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03983876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*